Our R&D Pipeline
Neurology Pipeline
Osmotica has focused its proprietary development program on developing improved therapies for the treatment of neurological disorders. Currently development is focused on numerous innovative product candidates to address the special needs of the Parkinson's patient. Our Research and Development team along with our Scientific Advisory Board are routinely evaluating new development product concepts for the treatment of Parkinson's disease and related neurological disorders.
| Product | Indication | Status |
| OS - 320 | Treatment of complications of Parkinson's disease | Phase II study completed |
| OS - 440 | Treatment of Spasticity | Pre-Clinical |
OVERVIEW
OUR BUSINESS
OUR HISTORY
OUR LOCATIONS
DEVELOPMENT FACILITIES
OUR MANAGEMENT TEAM
OUR BOARD OF DIRECTORS
OUR INVESTORS
OUR EMPLOYEES
WHAT'S NEW
OVERVIEW
PARTNERING WITH OSMOTICA
OUT-LICENSING OPPORTUNITIES
IN-LICENSING INTERESTS
PROJECT MANAGEMENT
OVERVIEW
OSMODEX FAMILY
OTHER TECHNOLOGIES
INTELLECTUAL PROPERTY
R&D STRATEGY
NEUROLOGY PIPELINE
PARTNERED PIPELINE
TECHNOLOGY PIPELINE
SCIENTIFIC ADVISORY BOARD
LICENSED PRODUCTS
APPROVED IN U.S.
APPROVED IN OTHER COUNTRIES
CONTACT US